Company intelligence / Profile preview

OrisDX

Chicago, Illinois, USA

Ownership: Private
Development stage: Preclinical

Overview

OrisDX has developed a non-invasive, saliva-based molecular diagnostic test that detects more than 93% of oral cancers with high sensitivity and specificity. The technology leverages next-generation sequencing of genetic biomarkers from saliva to enable early detection of oral squamous cell carcinoma. Clinical studies have validated the accuracy of the test, which aims to improve patient outcomes by enabling earlier diagnosis compared to traditional biopsy methods.

Therapeutic areas: Oncology
Modalities: Diagnostic test (Salivary diagnostic platform)Next-generation sequencing-based diagnosticsMultiomic analysis (genomics, molecular biomarkers)
Industry: Molecular Diagnostics

Beyond the preview

Go deeper on OrisDX.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OrisDX.

Explore the full profile